Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing for the latter’s ...
Insmed is set to challenge the Duchenne muscular dystrophy (DMD) treatment space with its innovative gene therapy asset, ...
The combination therapy is intended to treat NSCLC in individuals with ... Last September, the company reported outcomes from the Phase II SKIPPirr study, which focused on intravenous Rybrevant for ...
This is a MedPage Today story. In late September, Hurricane Helene damaged a major supplier of intravenous (IV) fluids. In this report, we follow up on what has happened since. Hurricane Helene ...
Copyright 2025 The Associated Press. All Rights Reserved. Jacob Bullard warms up on an elliptical machine while undergoing physical therapy at WashU, Monday, Dec. 16 ...